title: Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study.
abstract: BACKGROUND
  The oral prednisolone test is widely used to distinguish chronic obstructive pulmonary disease (COPD) patients who might benefit from inhaled steroid treatment. Previous studies used selected patient groups that did not represent the large COPD population in primary care.
  
  
  METHODS
  The study included smokers and exsmokers with chronic bronchitis or COPD from primary care, who underwent prednisolone testing (30 mg for 14 days) before randomization in a three-year follow-up randomized controlled trial (COOPT Study). Spirometry was performed before and after the test. Responders and nonresponders were classified according to international criteria. Effectiveness of inhaled fluticasone relative to placebo was compared in terms of health status (Chronic Respiratory Disease Questionnaire), exacerbations, and postbronchodilator forced expiratory volume in one second (FEV(1)), using repeated measurement analysis.
  
  
  RESULTS
  Two hundred eighty-six patients recruited from 44 primary care practices were randomized. Nine percent to 16% of the COPD population was classified as responder, depending on the international guideline criteria used. On average, responders did not reach the minimum clinically important difference in health status (0.29 points/year, P = 0.05), although a borderline significant effect of inhaled fluticasone was noted. Possible clinically relevant reductions in exacerbation rate (rate ratio 0.67) and FEV(1) decline (39 mL/year) occurred in responders, but did not reach statistical significance.
  
  
  CONCLUSIONS
  Oral steroid testing identifies a limited proportion of COPD patients, but does not reveal any clinically relevant benefit from inhaled steroid treatment on health status. No significant effects on exacerbation rate and lung function decline occurred.
authors.affiliation: Department of Public health and Primary Care, Leiden University Medical Center, The Netherlands. n.h.chavannes@lumc.nl
authors.forename: Niels H
authors.initials: NH
authors.lastname: Chavannes
authors.forename: Tjard R J
authors.initials: TR
authors.lastname: Schermer
authors.forename: Emiel F M
authors.initials: EF
authors.lastname: Wouters
authors.forename: Reinier P
authors.initials: RP
authors.lastname: Akkermans
authors.forename: Richard P N
authors.initials: RP
authors.lastname: Dekhuijzen
authors.forename: Jean W M
authors.initials: JW
authors.lastname: Muris
authors.forename: Chris
authors.initials: C
authors.lastname: van Weel
authors.forename: Onno C P
authors.initials: OC
authors.lastname: van Schayck
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D017063:Outcome Assessment, Health Care; D018579:Patient Selection; D011237:Predictive Value of Tests; D011239:Prednisolone / Q000008:administration & dosage*; D011320:Primary Health Care; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone